Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Cln2 Treatment

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Completed1
Enrolling By Invitation1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT04098211Active Not RecruitingPrimary

Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients

NCT03862274Enrolling By Invitation

Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease

NCT04808297CompletedPrimary

Trehalose in Subjects With Neuronal Ceroid Lipofuscinoses

Showing all 3 trials

Research Network

Common Treatments

  • Cln2 Treatment1

Active Sponsors

  • BioMarin Pharmaceutical1
  • Children's Hospital of Orange County1
  • IRCCS Fondazione Stella Maris1
  • Jessica Scherr1

Top Investigators

Related Conditions

  • Neuronal Ceroid Lipofuscinosis Cln21
  • Batten Disease1
  • Spinocerebellar Ataxia Autosomal Recessive 71
  • Cln21

Activity Timeline